During the past decade, Jae Hui Kim conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Jae Hui Kim" #1 collaborator was "Bayer" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Jae Hui Kim" are "Age-related Macular Degeneration" (1 trials) and "Retinal Angiomatous Proliferation" (1 trials). Many other conditions were trialed in "Jae Hui Kim" in a lesser frequency.

Most popular intervention types in "Jae Hui Kim" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept Injection" (1 trials) and "Intravitreal anti-vascular endothelial growth factor injection" (1 trials). Other intervention names were less common.

The vast majority of trials in "Jae Hui Kim" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Jae Hui Kim". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Jae Hui Kim, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Jae Hui Kim, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".